Midazolam Fagron neusspray: from preparation to registration

Soon we will launch Midazolam Fagron nasal spray, a registered unit dose in three strengths for the treatment of acute epileptic seizures.

Until then, the current nasal spray preparations will remain available, dispensed to your patients and reimbursed untill further notice.

Therapeutic indications

Midazolam Fagron nasal spray is a soporific and anticonvulsant medicine indicated for: 

  • the treatment of prolonged acute convulsive seizures;
Parents/carers should use Midazolam Fagron nasal spray only if the patient has been diagnosed with epilepsy.
  • for moderate sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia;
  • as premedication before induction of anaesthesia
Only healthcare professionals should use Midazolam Fagron nasal spray for moderate sedation or as premedication.

Midazolam Fagron nasal spray is indicated for use in adults and children ≥12 kg from the age of 2 years. For more information about this product, please see the SmPC and/or the package leaflet on the CBG website.

Fagron Midazolam nasal spray instructions for use

Request form

Use this form to request the available instructional materials

Request form
Instruction card

Use of Fagron Midazolam nasal spray for epileptic seizures

Download
Instruction video

Watch the video to learn how to use the nasal spray correctly

Watch video
Training, presentation and webinar replay

Are you a healthcare professional interested in learning more about the use of Midazolam Fagron nasal spray and the transition from preparation to registration?

Then sign up for a short presentation and training at your pharmacy.

You can also request the link to replay the webinar 'Midazolam Fagron nasal spray from preparation to registration'.

Sign up

Midazolam Fagron neusspray: from preparation to registration

Soon we will launch Midazolam Fagron nasal spray, a registered unit dose in three strengths for the treatment of acute epileptic seizures.

Until then, the current nasal spray preparations will remain available, dispensed to your patients and reimbursed untill further notice.

Therapeutic indications

Midazolam Fagron nasal spray is a soporific and anticonvulsant medicine indicated for: 

  • the treatment of prolonged acute convulsive seizures;
Parents/carers should use Midazolam Fagron nasal spray only if the patient has been diagnosed with epilepsy.
  • for moderate sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia;
  • as premedication before induction of anaesthesia
Only healthcare professionals should use Midazolam Fagron nasal spray for moderate sedation or as premedication.

Midazolam Fagron nasal spray is indicated for use in adults and children ≥12 kg from the age of 2 years. For more information about this product, please see the SmPC and/or the package leaflet on the CBG website.

Fagron Midazolam nasal spray instructions for use

Request form

Use this form to request the available instructional materials

Request form
Instruction card

Use of Fagron Midazolam nasal spray for epileptic seizures

Download
Instruction video

Watch the video to learn how to use the nasal spray correctly

Watch video
Training, presentation and webinar replay

Are you a healthcare professional interested in learning more about the use of Midazolam Fagron nasal spray and the transition from preparation to registration?

Then sign up for a short presentation and training at your pharmacy.

You can also request the link to replay the webinar 'Midazolam Fagron nasal spray from preparation to registration'.

Sign up